A Phase 1 Study Of Pf-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (Nhl)
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2017
At a glance
- Drugs Utomilumab (Primary) ; Rituximab
- Indications B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 24 Jul 2017 Planned End Date changed from 19 Oct 2019 to 2 Aug 2019.
- 24 Jul 2017 Planned primary completion date changed from 19 Dec 2017 to 29 Jan 2018.
- 10 Jun 2017 Biomarkers information updated